Novo Sues Rival Lilly Over Weight-Loss
Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading about obesity drugs in the US. Novo
Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo's Wegovy to Lilly's Zepbound.
John Kuckelman, Novo Norddisk Group general counsel and senior vice president, speaks on "Bloomberg Open Interest." Lilly has not responded to a request for comment. More on Bloomberg Television and Markets Like this video?
Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance Visit for business news & analysis, up-to-the-minute market data, features, profiles and more. Connect with Bloomberg
Television on Connect with Bloomberg Business on TikTok Reddit More from Bloomberg Bloomberg Radio Bloomberg Surveillance Bloomberg Politics Bloomberg Originals Watch more on Bloomberg Technology Bloomberg Originals Bloomberg Quicktake Bloomberg Espanol Bloomberg Podcasts
The BriefWire